Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?
Amedeo Lonardo, Fabio Nascimbeni, Alessandro Mantovani, et al.
Journal of Hepatology (2017) Vol. 68, Iss. 2, pp. 335-352
Closed Access | Times Cited: 625

Showing 1-25 of 625 citing articles:

AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Mary E. Rinella, Brent A. Neuschwander‐Tetri, Mohammad Shadab Siddiqui, et al.
Hepatology (2023) Vol. 77, Iss. 5, pp. 1797-1835
Open Access | Times Cited: 1137
The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments
Giovanni Targher, Kathleen E. Corey, Christopher D. Byrne, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 9, pp. 599-612
Closed Access | Times Cited: 580
NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
Giovanni Targher, Christopher D. Byrne, Herbert Tilg
Gut (2020) Vol. 69, Iss. 9, pp. 1691-1705
Open Access | Times Cited: 578
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
Martín Cowie, Miles Fisher
Nature Reviews Cardiology (2020) Vol. 17, Iss. 12, pp. 761-772
Closed Access | Times Cited: 574
Epidemiological Features of NAFLD From 1999 to 2018 in China
Jianghua Zhou, Feng Zhou, Wenxin Wang, et al.
Hepatology (2020) Vol. 71, Iss. 5, pp. 1851-1864
Closed Access | Times Cited: 525
Global liver disease burdens and research trends: Analysis from a Chinese perspective
Jia Xiao, Fei Wang, Nai-Kei Wong, et al.
Journal of Hepatology (2019) Vol. 71, Iss. 1, pp. 212-221
Open Access | Times Cited: 437
Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association
P. Barton Duell, Francine K. Welty, Michael Miller, et al.
Arteriosclerosis Thrombosis and Vascular Biology (2022) Vol. 42, Iss. 6
Open Access | Times Cited: 383
Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals
Alessandro Mantovani, Graziana Petracca, Giorgia Beatrice, et al.
Gut (2020) Vol. 70, Iss. 5, pp. 962-969
Open Access | Times Cited: 355
NAFLD as a driver of chronic kidney disease
Christopher D. Byrne, Giovanni Targher
Journal of Hepatology (2020) Vol. 72, Iss. 4, pp. 785-801
Open Access | Times Cited: 347
Nonalcoholic Fatty Liver Disease and the Heart
Eric Stahl, Devinder S. Dhindsa, Suegene Lee, et al.
Journal of the American College of Cardiology (2019) Vol. 73, Iss. 8, pp. 948-963
Closed Access | Times Cited: 335
Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis
Alessandro Mantovani, Gianluigi Zaza, Christopher D. Byrne, et al.
Metabolism (2017) Vol. 79, pp. 64-76
Open Access | Times Cited: 294
Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology
Mohammed Eslam, Jacob George
Nature Reviews Gastroenterology & Hepatology (2019) Vol. 17, Iss. 1, pp. 40-52
Closed Access | Times Cited: 268
Macrophages in obesity and non-alcoholic fatty liver disease: Crosstalk with metabolism
Sander Lefere, Frank Tacke
JHEP Reports (2019) Vol. 1, Iss. 1, pp. 30-43
Open Access | Times Cited: 234
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Seong Hee Kang, Hye Won Lee, Jeong‐Ju Yoo, et al.
Clinical and Molecular Hepatology (2021) Vol. 27, Iss. 3, pp. 363-401
Open Access | Times Cited: 222
The crucial role and mechanism of insulin resistance in metabolic disease
Xuefei Zhao, Xuedong An, Cunqing Yang, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 206
Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 202
Nonalcoholic Fatty Liver Disease
Yan-Ci Zhao, Guojun Zhao, Ze Chen, et al.
Hypertension (2019) Vol. 75, Iss. 2, pp. 275-284
Open Access | Times Cited: 188
Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways
Olufunto O. Badmus, Sarah A. Hillhouse, Christopher D. Anderson, et al.
Clinical Science (2022) Vol. 136, Iss. 18, pp. 1347-1366
Open Access | Times Cited: 174
Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview
Simona Marchisello, Antonino Di Pino, Roberto Scicali, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 8, pp. 1948-1948
Open Access | Times Cited: 170
Treatments for NAFLD: State of Art
Alessandro Mantovani, Andrea Dalbeni
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 5, pp. 2350-2350
Open Access | Times Cited: 161
The associations between modifiable risk factors and nonalcoholic fatty liver disease: A comprehensive Mendelian randomization study
Jiarong Xie, Hangkai Huang, Zhening Liu, et al.
Hepatology (2022) Vol. 77, Iss. 3, pp. 949-964
Open Access | Times Cited: 161
Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease
Soo Lim, Jin‐Wook Kim, Giovanni Targher
Trends in Endocrinology and Metabolism (2021) Vol. 32, Iss. 7, pp. 500-514
Closed Access | Times Cited: 151
Management of non-alcoholic fatty liver disease
Maria Letizia Petroni, Lucia Brodosi, Elisabetta Bugianesi, et al.
BMJ (2021), pp. m4747-m4747
Open Access | Times Cited: 148
Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease
Atsushi Nakajima, Yuichiro Eguchi, Masato Yoneda, et al.
Alimentary Pharmacology & Therapeutics (2021) Vol. 54, Iss. 10, pp. 1263-1277
Open Access | Times Cited: 146
The role of hepatokines in NAFLD
Norbert Stefan, Fritz Schick, Andreas L. Birkenfeld, et al.
Cell Metabolism (2023) Vol. 35, Iss. 2, pp. 236-252
Open Access | Times Cited: 141
Page 1 - Next Page

Scroll to top